Viibryd also caused diarrhea in 28% of patients and nausea in 23%, both triple placebo.
FORBES: Clinical Data Could Use More Data
In neither case was there a close to significant difference between Viibryd and placebo.
His next big score could come from his biotech company Clinical Data, whose antidepressant Viibryd was approved in January.
FORBES: The Next Big Move For The Smartest Biotech Investor
应用推荐
模块上移
模块下移
不移动